Developing New Antibiotics: What's the Best Approach to Take?
AUG 22, 2017 | CONTAGION® EDITORIAL STAFF
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, discusses the three choices that developers have when it comes to the approach they can take for developing a new antibiotic. Dr. Pilch shares the two areas in which he and his team's approach to treating drug-resistant bacteria has been focused.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512